Crossject, a specialty pharmaceutical company developing needle-free auto-injectors dedicated to emergency situations, has engaged Syneos Health, a fully integrated leader in biopharmaceutical laboratory services to engage in preparation for the U.S. commercial launch of ZEPIZURE®, Crossject’s innovative emergency treatment for the management of epileptic seizures.
As part of this agreement, Syneos Health will provide support for all pre-launch and launch activities for ZEPIZURE®. Syneos Health will allow Crossject to benefit from its strong presence in the United States and its great expertise in bringing new treatments to the market.
“ZEPIZURE® is a unique treatment that could save lives in an emergency situation because it can potentially be administered anywhere and by anyone in seconds,” said Patrick Alexandre, CEO of Crossject. “Now we are focused on preparing our FDA marketing authorization application, and we are pleased to have such an experienced partner as Syneos Health on board to support us in the launch of our business activities in the United States. »
ZEPIZURE® is based on Crossject’s patented, needle-free ZENEO® device, developed to easily administer injections in a fraction of a second in emergency situations.